There is a health technology appraisal request that Bloodwise need help with. The request is for a NICE appraisal of venetoclax in combination with rituximab for treating relapsed or refractory CLL.
Ideally, we are looking for someone who has had the treatment. However if you haven’t, but still have insight into this treatment, it would be hugely helpful to speak with you about it.
If this is something that applies to you or would be happy/interested to help with, please could you get in touch with our Policy Officer Charlotte Cherry on ccherry@bloodwise.org.uk ASAP.
The deadline for the NICE submission is June 22nd- short notice - I apologise -however we feel that it will have a large impact on CLL so would be great if you can help!
Message to Bloodwise Ambassadors from
Grace Harington
Volunteer and Ambassador Coordinator
T: 020 7504 2238
E: gharington@bloodwise.org.uk
W: bloodwise.org.uk
How you can help make ibrutinib plus venetoclax fixed duration therapy a reality for Australians with previously untreated CLL
